| Home | E-Submission | Sitemap | Contact Us
JPTM > Ahead-of Print

doi: https://doi.org/10.4132/jptm.2017.10.20    [Epub ahead of print]
The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma
Yumin Chung1, Young Chan Wi1, Yeseul Kim1, Seong Sik Bang1, Jung-Ho Yang2, Kiseok Jang1, Kyueng-Whan Min1, Seung Sam Paik1
1Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
2Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Corresponding Author: Kyueng-Whan Min ,Tel: +82-31-560-2496, Fax: +82-31-560-2339, Email: kyueng@gmail.com
Received: July 31, 2017;  Revised: September 19, 2017  Accepted: October 16, 2017.  Published online: October 23, 2017.
Background: Smad4 and PTEN are prognostic indicators for various tumor types. Smad4 regulates tumor suppression, whereas PTEN inhibits cell proliferation. We analyzed and compared the performance of Smad4 and PTEN for predicting the prognosis of patients with colorectal adenocarcinoma. Methods: Combined expression patterns based on Smad4+/- and PTEN+/- statuses were evaluated by immunostaining using a tissue microarray with samples from patients with colorectal adenocarcinoma. The relationships between protein expression and clinicopathological variables were analyzed. Results: Smad4-/PTEN- status was most frequently observed in metastatic adenocarcinoma, followed by primary adenocarcinoma and tubular adenoma (p < 0.001). Compared with the Smad4-/PTEN- and Smad4+/PTEN+ groups, Smad4-/PTEN- status was associated with high N stage (p = 0.018) and defective mismatch repair proteins (p = 0.006). Significant differences in disease-free survival and overall survival were observed among the three groups (Smad4+/PTEN+, Smad4-/PTEN+ or Smad4+/PTEN-, and Smad4-/PTEN-) (all p < 0.05).
Concurrent loss of Smad4 and PTEN may lead to more aggressive disease and poorer prognosis in patients with colorectal adenocarcinoma compared to the loss of Smad4 or PTEN alone.
Key Words: Smad4; PTEN; Prognosis; Colon Neoplasms; Human